🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/09/2005 | 19,00 | 19,49 | 18,92 | 19,43 | +2,48% | 3,00% | 1.574.600 |
| 23/09/2005 | 18,63 | 18,98 | 18,33 | 18,96 | +2,16% | 3,49% | 1.082.500 |
| 22/09/2005 | 19,10 | 19,15 | 18,49 | 18,56 | -2,47% | 3,46% | 811.200 |
| 21/09/2005 | 19,14 | 19,39 | 18,88 | 19,03 | -0,42% | 2,66% | 897.600 |
| 20/09/2005 | 19,23 | 19,63 | 18,98 | 19,11 | -0,88% | 3,38% | 1.359.500 |
| 19/09/2005 | 19,22 | 19,62 | 19,22 | 19,28 | -0,62% | 2,08% | 721.900 |
| 16/09/2005 | 18,87 | 19,82 | 18,87 | 19,40 | +2,54% | 5,03% | 2.471.800 |
| 15/09/2005 | 18,50 | 19,00 | 18,45 | 18,92 | +2,99% | 2,97% | 880.100 |
| 14/09/2005 | 18,79 | 19,01 | 18,24 | 18,37 | -2,86% | 4,10% | 697.100 |
| 13/09/2005 | 18,78 | 18,98 | 18,60 | 18,91 | +1,07% | 2,02% | 987.400 |
| 12/09/2005 | 18,42 | 18,96 | 18,35 | 18,71 | +1,24% | 3,31% | 890.400 |
| 09/09/2005 | 18,00 | 18,50 | 18,00 | 18,48 | +2,44% | 2,78% | 930.700 |
| 08/09/2005 | 18,20 | 18,55 | 17,84 | 18,04 | -0,93% | 3,90% | 489.100 |
| 07/09/2005 | 18,17 | 18,32 | 17,42 | 18,21 | +1,00% | 4,95% | 760.300 |
| 06/09/2005 | 17,94 | 18,47 | 17,93 | 18,03 | +0,73% | 3,01% | 958.200 |
| 02/09/2005 | 18,25 | 18,49 | 17,86 | 17,90 | -2,35% | 3,45% | 706.900 |
| 01/09/2005 | 18,45 | 18,55 | 18,02 | 18,33 | -0,38% | 2,87% | 907.100 |
| 31/08/2005 | 17,76 | 18,58 | 17,71 | 18,40 | +3,14% | 4,90% | 1.007.800 |
| 30/08/2005 | 17,93 | 17,99 | 17,62 | 17,84 | -0,50% | 2,06% | 1.232.100 |
| 29/08/2005 | 17,32 | 17,93 | 17,23 | 17,93 | +2,75% | 4,04% | 653.800 |
| 26/08/2005 | 17,90 | 17,91 | 17,40 | 17,45 | -2,51% | 2,85% | 732.000 |
| 25/08/2005 | 18,16 | 18,46 | 17,80 | 17,90 | -0,83% | 3,63% | 699.300 |
| 24/08/2005 | 17,91 | 18,56 | 17,80 | 18,05 | +0,89% | 4,24% | 890.700 |
| 23/08/2005 | 18,40 | 18,40 | 17,71 | 17,89 | -2,24% | 3,75% | 1.818.400 |
| 22/08/2005 | 18,93 | 19,01 | 17,93 | 18,30 | -2,66% | 5,71% | 2.269.400 |
| 19/08/2005 | 17,14 | 19,20 | 17,13 | 18,80 | +14,84% | 12,08% | 7.458.700 |
| 18/08/2005 | 16,49 | 16,51 | 16,17 | 16,37 | -0,85% | 2,06% | 686.700 |
| 17/08/2005 | 16,55 | 16,76 | 16,40 | 16,51 | -0,06% | 2,18% | 592.000 |
| 16/08/2005 | 17,06 | 17,19 | 16,50 | 16,52 | -2,99% | 4,04% | 1.181.800 |
| 15/08/2005 | 16,92 | 17,08 | 16,84 | 17,03 | +0,59% | 1,42% | 929.700 |